July 26, 2017
PCMA requested that Milliman estimate the value of direct and indirect remuneration (DIR) for Medicare Prescription Drug Plan (PDP) stakeholders....
Filter by:
Choose a Topic
Filter by Year:Clear Filters- Research
- Biosimilars
- Drug Abuse Prevention
- Drug Adherence Programs
- Drug Cost Management
- Drug Coupons & Assistance Programs
- Drug Coverage Mandates
- Drug Price Negotiations & Rebates
- Employers, Unions, & Insurers
- FEHB Program
- Formulary Design
- Fraud, Waste, & Abuse
- Generic Drug Utilization
- Health Insurance Marketplace (ACA)
- Home Delivery of Drugs
- Medicaid
- Medicare Part D
- Patient Cost Sharing
- Pharmacy Networks
- Pharmacy Reimbursement & Contracting
- REMS Management
- Specialty Benefit Design
- Specialty Pharmacies
- Specialty Pharmacy Networks
- TRICARE
June 29, 2017
PCMA requested that Milliman estimate the impact of shifting price concessions reflected as DIR to price concessions at the POS...
June 13, 2017
Pharmaceutical Care Management Association Statement for the Record Prepared for the UNITED STATES SENATE COMMITTEE ON HEALTH, EDUCATION, LABOR, and...
Increasing Prices Set by Drug Makers Not Correlated With Rebates
June 09, 2017
As the debate over high drug prices has intensified, drug makers have attempted to shift focus away from the increasing...
PBMs Provide Clinical Value to Patients, Doctors and Other Healthcare Providers
May 01, 2017
Pharmacy Benefit Managers (PBMs) are critical to the delivery of high-quality, cost-effective healthcare. PBMs have long been recognized for their...
How the Next FDA Commissioner Can Address Drug Prices by Promoting Drug Competition
April 26, 2017
Pharmaceutical competition is critical to the U.S. health care system. It yields cost savings, as both generic drugs and competing...
April 21, 2017
The Moran Company was engaged by the Pharmaceutical Care Management Association (PCMA), the trade association of PBM companies, to evaluate...
No Correlation Between Increasing Drug Prices and Manufacturer Rebates in Major Drug Categories
April 19, 2017
Visante conducted an analysis of SSR Health data to see if there is a correlation between the prices that drug...
Survey: Consumers Hold Drug Companies Responsible for High Prices and Out-of-Pocket Costs
November 30, 2016
A new national survey finds most voters blame drug companies not only for high drug prices, also for out-of-pocket costs...
The Return on Investment (ROI) on PBM Services
November 21, 2016
An analysis from Visante quantifying how PBMs generate $6 in savings for each $1 spent on their services. Major Findings...
Medicaid Pharmacy Savings Opportunities: National and State-Specific Estimates
October 13, 2016
Executive Summary This study examines whether the full range of pharmacy benefit management (PBM) tools are being allowed and used...
Report: Comparison of Hepatitis C Treatment Costs
September 23, 2016
A report from IMS Institute for Healthcare Informatics shows Hepatitis C drug prices, specifically negotiated by pharmacy benefit managers (PBMs)...